key: cord-0994227-mkabcvkw
authors: El‐Sharkawi, Dima; Iyengar, Sunil
title: Haematological Cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date
date: 2020-06-19
journal: Br J Haematol
DOI: 10.1111/bjh.16956
sha: 07a0499569172291bf030c69932f90e17207442a
doc_id: 994227
cord_uid: mkabcvkw

From the outset of the COVID‐19 pandemic, patients and health care professionals have been concerned that a history of haematological malignancy will lead to an increased risk of severe COVID‐19. This led to the UK government advising patients with blood cancers to shield, massive re‐organisation of NHS haematology and cancer services, and changes in treatment plans for thousands of patients. Given the unknown effects that relaxation of social distancing measures will have on the infection rate, we review the evidence to date to see whether a history of haematological malignancy is associated with increased risk of COVID‐19. Multivariable analysis of large population studies, taking other known risk factors into account do indicate that patients with haematological malignancy, especially those diagnosed recently are at increased risk of death with COVID‐19 compared to the general population. The evidence that this risk is higher than for those with solid malignancies is conflicting. There is suggestive evidence from smaller cohort studies that those with myeloid malignancy may be at increased risk within the blood cancer population, but this needs to be confirmed on larger studies. Ongoing large collaborative efforts are required to gain further evidence regarding specific risk factors for severe complications of COVID‐19.

least 9 patients with haematological malignancies (where specified) have been included in a summary table.

All studies that have included at least 9 patients with haematological malignancies (where specified) and COVID-19 are summarised in Table 1 .

The prevalence of cancer in cohorts of patients admitted with COVID-19 has been elucidated and compared to the prevalence of cancer in the general population by several groups. In a cohort of 1590 COVID-19 patients admitted into hospitals in China, Liang et al 5 found 18 with a history of cancer (including 1 lymphoma patient) (1%; 95% CI 0.61-1.65) which was reported as higher than the overall incidence of cancer in the Chinese population at 0.29%. Subsequent studies have also reported slightly higher prevalence of cancer in Chinese populations with COVID-19 of 2.5% in 8161 patients and 2.7% in 1380 patients. 6, 7 A meta-analysis of 11 published studies reporting prevalence of cancer in patients with COVID-19 (including Liang et al) found the overall prevalence to be 2% (95% CI 2-3%), this was unadjusted for age and co-morbidities. 8 A large UK wide study is collecting the baseline characteristics of 20133 patients admitted into 208 hospitals for COVID-19, at time of publication the malignancy history is known for 17354 patients of whom 10% had a history of cancer, the initial publication has not detailed the malignancy types. 9 Whilst these studies indicate that the prevalence of cancer in patients with COVID-19 may be higher than in the general population, not all studies have found this to be the case. For example, in 1307 patients who were admitted to intensive care units in Russia, only 2.4% had a history of cancer (none of which were haematological) and the authors concluded this was a similar prevalence to the general population. 10 Zhou et al 11 showed that in 191 patients who were admitted into one of two hospitals in the Wuhan province only 2 had a history of carcinoma. Other cohorts (n= 41-201) of patients with COVID-19 have also been published with only 1 patient with malignancy in each of the cohorts. [12] [13] [14] [15] The converse prevalence has also been investigated by many groups, i.e. the prevalence of COVID-19 in cancer patients. Yu et al 16 

This article is protected by copyright. All rights reserved in 530 patients with CML in the community through patient completed surveys and found that 5 had a history of COVID-19 and that this rate of 0.9% was higher than 0.1% in the general population during the same period. However, another group compared the rate of COVID-19 development in inpatients at a single centre to the rate in health care professionals working at the same site and found it to be similar (10% versus 7%). 18 Is going to hospital for the treatment or monitoring of malignancy a risk factor for developing COVID-

Several groups stated that many of the cancer patients that developed COVID-19 had either been inpatients or visited the hospital in the 14 days prior to the diagnosis of COVID-19 suggesting this may have been an exposure risk. For example He et al 18 noted that a cluster of 16 cases of both patients and health care professionals who subsequently developed COVID-19 were all based in the intensive care unit.

Of the 61 patients who died due to COVID-19 in a New York centre, 37 were either residents in nursing homes or had been in hospitals in the 30 days prior to diagnosis. 19 A single centre examined the outcomes of all their stem cell patients who developed COVID-19, all 7 were either inpatients or requiring weekly visits to hospital. 20

In patients hospitalised with COVID-19, is there a higher risk of severe endpoints in patients with cancer?

The first paper to suggest that those with cancer may have a worse outcome was the cohort study by Liang et al 5 , the 18 patients with cancer in this cohort had a higher risk of severe events (composite endpoint of being admitted to ICU, requiring invasive ventilation, death) compared to patients without cancer, 7/18 versus 124/1572 (p= 0.0003), however the patients with cancer were older (63 years versus 48.7 years) and more likely to have a smoking history.

Since then, numerous small cohort studies of patients with COVID-19 and cancer have also been published and the outcomes compared to the published outcomes for the general population. Three papers retrospectively examined the characteristics of 28-67 patients with known cancer who were admitted with COVID-19 within a total of 8 centres all located in Wuhan, China. 21 

This article is protected by copyright. All rights reserved A Spanish group reported a mortality rate of 32% in 33 patients with haematological malignancies who were admitted with COVID-19. 24 Being male and older age was associated with worse outcome. Age did not remain significant on multi-variate analysis although in this study it was considered a binary variable of below or above 80 years. Similarly, in a single centre French study, 52% of 25 patients with haematological malignancy and COVID-19 developed ARDS, and 9 subsequently died, however 92% of this population had co-morbidities and 7 were not taken to ICU due to age, and co-morbidities. 25 A high mortality rate of 40% was also seen in a cohort of 35 patients with haematological malignancy in a single UK centre. 26 The outcome of 75 patients with myeloma who developed PCR confirmed COVID-19 was analysed in a UK based audit, the mortality rate in this cohort was 54.6%, however the survivors were significantly younger than the non-survivors (66 vs 78 yrs, p=0.017). 27 To try and mitigate for the confounding factor of age when comparing the outcomes of patients with and without cancer, some groups have compared their cancer cohorts with age matched controls. He et al 18 compared the fatality rate of 62% in 13 cancer patients compared to 0% in 11 health care professionals with no significant difference in age, however 8 of these patients were already in ICU prior to contracting COVID-19. The characteristics of 25 patients with cancer (2 patients with haematological malignancy) and laboratory confirmed COVID-19 was examined by Stroppa et al 28 and the survival compared to that of a control group of 31 patients who were also hospitalised and matched for age, sex, pneumonia and antiviral treatment. The mortality rate was 36% compared to 16% in the control group (p=0.12) although co-morbidities were not listed in the control group whereas most of the cancer cohort had co-morbidities.

A multicentre study using information from 14 hospitals in the Hubei province in China, compared the outcomes of 105 hospitalised patients with cancer to 536 patients without cancer matched for age, hospital and date of admission. 29 Patients with cancer were more likely to have a smoking history but otherwise no statistical difference in co-morbidities, although there was a significantly higher number of patients with cancer who were being treated as inpatients compared to the patients without cancer (19% versus 1.5%, p<0.01). Lung cancer was the most frequent tumour type, 9 of 105 patients had a haematological cancer. The fatality rate within the cancer patient cohort was 11%. Comparing the cancer patient cohort to the control group, higher rates of ICU admission and death were seen in the cancer population and when multivariate logistic regression was performed adjusting for age, sex, smoking and co-morbidities, patients with cancer had an excess odds ratio of 2.17 of death. Another Chinese multicentre matched cohort study has been published more recently comparing the outcomes of 232 patients with cancer to 519 patients without a history of cancer, matched for age, sex and co-morbidities. 30 The mortality rate was 20% in the cancer cohort compared to 11% in the control group, p=0.0012. Patients

with cancer were more likely to have severe COVID-19 than patients without cancer, 148/232 vs 166/519 (OR 3·61, 95% CI 2·59-5·04, p<0·0001).

In New York, the outcome of 218 patients with a history of cancer and COVID-19 treated in a single centre was examined. 19 These included 164 patients with solid tumours and 54 with haematological malignancies. The fatality rate in this cohort was 28% overall with a higher rate of 55% in lung cancer patients and 37% in patients with haematological malignancies. Older age was associated with increased mortality as was co-morbidities. When age and sex matched to 1090 patients in the same hospital system, case fatality rates were elevated in all age cohorts. The fatality rate was also compared to the official rate published in New York which had a significantly lower fatality rate of 6%.

Most recently, large national and international collaborative groups as well as national surveillance The outcome of 5688 patients with COVID-19 in New York was analysed, 334 had a history of cancer (6%), although patients with cancer had a higher rate of intubation, the death rate was not significantly different (37/334 with a history of cancer compared to 518/5354 without cancer, relative risk 1.15, 95% CI 0.84-1.57). 33 Stratifying according to age, patients under 50 had a higher mortality rate if they had cancer but this difference was not seen in patients over 50 yrs of age. Co-morbidities were not detailed in this cohort.

The Italian National Institute of Health publish and update a report on all patients who die with PCR proven COVID-19, in the update based on available data by May 14 th , co-morbidities were known in 2848 of the 29,692 patient deaths reported. 34 Of the 2848 patients, 454 (15.9%) had been diagnosed with active cancer in the past 5 years. However, the majority of patients who died had at least 3 comorbidities, with hypertension, ischaemic heart disease and diabetes being the most frequent. Of the 65 patients under 40 years who died and in whom there was clinical information available, 53 had serious pre-existing pathologies although none listed as cancer and 12 had no major pathologies. It should also be Accepted Article noted that all deaths regardless of cause were counted in the rate if a positive COVID-19 swab was detected. 35 The Chinese Centre for disease control and prevention showed that among 44672 confirmed cases of COVID-19, the case fatality rate was 2.3%. 36 This rose to 8% in those aged 70-79 and to 14.8% in those aged 80 and over. The case fatality rate (CFR) was also elevated in those with co-morbidities at 5.6% for cancer, however this is not split according to age.

In the study by Docherty et al 9 , the 1743 patients with a history of malignancy had a HR for death of 1.13 (95% CI 1.02-1.24, p= 0.017). Another large study, OpenSafely Collaborative in the UK used a platform allowing comparison of the characteristics and co-morbidities of 24 million patients from GP records to the rate of these characteristics in those who had died in hospital due to COVID-19. 37 These hazard ratios did not change significantly when fully adjusted for co-morbidities.

In patients with cancer, are there any specific risk factors that are associated with increased risk of severe outcome?

Two of the smaller cohort studies suggested that those with haematological malignancy were at increased risk of severe outcomes (Table 1) . 21, 29 This has been confirmed in the larger study by the OpenSAFELY collaborative where the HR of death comparing those diagnosed with haematological malignancy within 1 year to none was higher than those diagnosed with solid cancer within a year, HR 3.52 (95% CI 2.41-5.14) compared to 1.56 (1.29-1.89), however a direct pairwise comparison of the two was not performed. 37 Similarly, in the UK cancer cohort study (CCMP), those with non-lymphoma haematological malignancy had a OR of death of 1.57 (95% CI 1.01-2.42, p=0.04). 38 However, not all large cancer cohorts have found those with haematological malignancy to have a worse outcome, as Kuderer et al 39 Some of the studies have gone further to suggest that those with myeloid malignancies may have a worse outcome compared to other haematological malignancies. 19, 24, 38 Accepted Article This article is protected by copyright. All rights reserved The length of time since diagnosis of the cancer has also been shown to be associated with outcome, with those more recently diagnosed more likely to have a worse outcome, for example patients with a haematological diagnosis within a year of developing COVID-19 had a HR of 3.52 of death (95% CI 2.41-5.14) in multivariate analysis compared to 1.88 (95% CI 1.55-2.29) in those diagnosed over 5 years ago. 37 Those with active disease have also been proposed to have a worse outcome compared to those with fully treated disease in large cancer cohorts as well as cohorts with haematological malignancy. 17, 24, 39 Many groups noted a worse outcome for those patients who had received anti-cancer treatment within the weeks prior to developing COVID-19. 5, 6, 22, 23 For example, the HR for developing a severe event for patients who had treatment within 14 days was 4.079 (95% CI 1.086-15.322, p=0.037) in a cohort of 28 patients. 23 However, this has not been seen in all studies, Lee et al 38 found no difference in mortality between those patients who had treatment within 4 weeks compared to those who had not, and Aries et al 26 stated that 15 of the patients who were having intensive chemotherapy regimes for haematological malignancy when they developed COVID-19 were still alive.

As the initial peak of cases of severe COVID-19 and its associated death toll begins to fall in the UK, it is important to evaluate the evidence so far regarding the risk of severe complications to patients with haematological malignancies. This will inform the advice we give to patients regarding whether there is an ongoing need to shield, and particularly as their families start to return to work and schools, what extra risk this may bring. Furthermore, this will also have an impact on whether we continue to give treatment both curative and for disease control or defer/abbreviate it due to perceived increased risk for patients with haematological malignancy. The key questions, which cannot be completely answered at present, are whether there is a difference in risk of getting COVID-19, and perhaps more importantly whether there is a risk of developing severe complications in patients with COVID-19 and haematological cancer compared to patients with other cancers and the general population, furthermore what is the degree of extra risk to this patient group. Understanding of these risks will only come from large population-based analysis of patients. Larger cohort studies with more uniform characteristics, for example, patients with a particular haematological cancer will provide us with more granularity, to allow us to understand whether there is a variation in that risk depending on type of malignancy or time or type of treatment.

The increased risk that having a current or previous diagnosis of solid or haematological malignancy has on developing COVID-19 has been investigated by several groups by investigating either the prevalence of

This article is protected by copyright. All rights reserved cancer in cohort studies of patients with COVID-19 or the COVID-19 infection rate in cohort studies of patients with cancer and comparing them to the rate of cancer or COVID-19 in the general population respectively.

These studies are at best hypothesis generating as they do not capture the true rates of all patients who contract SARS-CoV-2 and are skewed towards those who develop symptoms related to COVID-19 and therefore get tested. The overall limitation of the majority of these studies is the numerous confounding factors such as known shared risk factors and the high rate of concurrent co-morbidities, compounded by the small numbers in most of these studies. Differing levels of high-risk exposure may also lead to increased vulnerability in the cancer patient cohort, as numerous groups proposed that several of their patients had nosocomial transmission of COVID-19 either through clinic visits or as inpatients. Papers published to date that have examined the rate of cancer in cohorts of patients with COVID-19, have compared the prevalence to the prevalence in the general population, and have suggested due to the higher rate of cancer in the COVID-19 cohort, that this could be a risk factor. However, the incidence of cancer increases with age, with a 40% lifetime risk of developing any cancer. 40 To avoid these potential confounding factors, it is necessary to compare the cancer prevalence to an age and sex-matched population.

Perhaps the more clinically significant question that several groups have sought to address is whether a history of cancer in patients with COVID-19 a risk factor for worse outcome, defining this by risk of either "severe COVID-19", intubation, admission to intensive care or death or a composite of all of these. Some of the smaller studies report case fatality rates from 11%-62% but again the variation is likely to be due to the heterogeneity of the cohorts and the confounding factors. For example, He et al 18 beginning to be published will provide stronger evidence as to whether there is a difference in outcomes as they can account for age and co-morbidities. Two large studies from UK collaboratives both concluded that a history of malignancy was associated with an increased risk of death due to COVID-19. Docherty et al 9 demonstrated that in the 17173 patients with known medical history, the cohort with a history of cancer (n=1743) had a HR for death on multivariate analysis of 1.14 (95% CI 1.03-1.25, p=0.008) . The OpenSAFELY collaborative also showed a similar hazard ratio for solid malignancies but higher risk in those with haematological malignancies with HR for death 1.88 (95% CI 1.55-2.29) in those diagnosed over 5 years ago, rising to 3.52 (2.41-5.14) in those diagnosed within a year. 37 One of the strengths of this study is that the analysis was performed on the data from over 17 million patients from GP records rather than just analysis of the cohort who developed COVID-19, giving us perhaps one of the truest indicators of risk. Of course, this does not provide us with details of why patients with haematological malignancy have a higher risk of death, and indeed may be an underestimate of "true risk" if this at-risk population were shielding effectively.

Patients with cancer are a heterogeneous population and so there have been attempts to understand whether patients with certain cancers are more or less likely to have severe outcomes. Similarly, whether time since diagnosis, disease status, treatment status, and type of treatment are risk factors. A number of studies including those examining large populations do seem to suggest that patients with haematological malignancy have a higher risk or severe complications. Some of the studies focusing on cancer patients have also suggested that possibly patients with myeloid diseases are at higher risk, but this needs to be confirmed on larger studies. There is conflicting evidence in these early datasets regarding whether being on active treatment at time of diagnosis of COVID-19 is associated with worse outcome. 6, 26, 38 Type of cancer, disease status, and length of time since last treatment are all intimately related particularly within the haematological malignancy cohort. For example, the proposal that patients with AML, MDS or myeloproliferative disorders are at increased risk compared to those with lymphoid malignancies may be due to biological differences. However, many patients with a history of lymphoid malignancy will have been cured from their cancer, and not on active treatment and so it is difficult to

This article is protected by copyright. All rights reserved tease apart which is the more significant risk factor. Cohort studies of patients with a single disease entity may provide us more granularity.

There is suggestive evidence from large population-wide studies in which the age and co-morbidities of patients are known that patients with haematological malignancies are at increased risk of death from severe COVID-19 compared to the general population and possibly compared to patients with solid cancer although not all studies have found this difference. This risk is highest in those that have been diagnosed within the past 5 years, especially in those diagnosed within the past year. Smaller studies have suggested those with acute leukaemia, MDS or MPN are at highest risk, but this needs to be confirmed in larger studies. Ongoing active disease may be a confounding factor for these subgroups. Continued analysis of the data, particularly as testing becomes more widespread within the community is required to attain further understanding of the risk factors for development of severe COVID-19.

Collaborative national and international efforts, such as CCP-UK and OpenSAFELY collaborative, should continue to capture the characteristics of patients with COVID-19 and correlate this with their outcome.

Large cancer cohort studies such as UK Coronavirus Cancer Monitoring Project and Covid-19 and cancer consortium (CCC19) can provide us with more detail regarding risks within the cancer patient population whilst cohorts of single disease groups will allow us to start to understand the reasons for the increased risks.

DE and SI reviewed the literature, wrote the paper and approved the submitted version of the manuscript. Abbreviations: CI, 95% Confidence intervals; haem, haematological; HCP, health care professional; HR, hazard ratio; OR, odds ratio; pts, patients.

Potential factors that may lead to a difference in published outcomes to COVID-19 for patients with haematological malignancy compared to the rest of the population.

-Are cancer patients more likely to shield, even before advice was given by government? -Are cancer patients more likely to be exposed if requiring hospital visits? -Are cancer patients more likely to inform secondary care of symptoms due to direct access e.g. via specialist nurses?

-Are healthcare professionals more likely to test patients with a history of cancer for COVID-19? -Are cancer patients more likely to be admitted due to concern regarding cancer/ COVID-19? -Are patients with a limited prognosis for their cancer less likely to be treated aggressively or given organ support?

-Are patients with cancer more likely to contract COVID-19 if exposed to SARS-CoV-2 virus? -Are patients with cancer less likely to be asymptomatic/ have mild symptoms with COVID-19? -Is detection rate, accuracy of RT-PCR the same in cancer patients to general population? -Are patients with cancer more likely to develop ARDS once they have COVID-19? -Are patients with cancer more likely to develop secondary complications e.g. bacterial supraadded infection? -Is neutropenia, lymphopenia, or immunoparesis a risk factor for severe disease?

-Does anti-neoplastic treatment lead to increased risk of COVID-19 and its complications

-Are patients with cancer more likely to have co-morbidities that are associated with increased risk of severe complications? -Increased prevalence of cancer with increasing age -Increased prevalence of smoking history

Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human

Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Two Things about COVID-19 Might Need Attention

Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. The Lancet Oncology

Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Cancer in intensive care unit patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Epidemiological and clinical characteristics of 99 cases of

China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

COVID-19 in persons with chronic myeloid leukaemia

COVID-19 in persons with haematological cancers

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Covid-19 in Bone Marrow Transplant Recipients: Reflecting on a Single Centre Experience

Clinical characteristics and outcomes of cancer patients with COVID-19

A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies

COVID-19 outcomes in patients with hematologic disease

Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncology

Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak

Clinical characteristics and risk factors associated with COVID-19

disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Do Patients with Cancer Have a Poorer Prognosis of COVID-19?

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet

SEER Cancer Statistics Database

This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved